U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
				Application Number	Not Yet Assigned 10/8/4, 195		
INFORMATION DISCLOSURE			CLOSURE	Filing Date	Even Date Herewith		
STATEMENT BY APPLICANT		First Named Inventor	Johan FROSTEGARD				
		Group Art Unit	1641				
	(use as many	<i>sheets as</i> n	ecessary)	Examiner Name	L.CoolL		
Sheet	1	of	2	Attorney Docket Number	FROSTEGARD=1B		
		 -					

	U.S. PATENT DOCUMENTS					
Examiner nitials*	Cite No.1	Document Number Number-Kind Code ^{2 (I known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
WC.	AA	US-5,731,208	3-24-1998	HEINECKE		
		us-	- -		:	
		US-			:	
-		US-				
		US-				
		US-				
		us-				
		US-				
		US-				
		US-			:	
		US-			:	
		US-				
		US-			:	
		us-			:	
		US-				
		US-				
		US-			:	

	FOREIGN PATENT DOCUMENTS									
Examiner Cite		Foreign Patent Number Country Code ³ Number ⁸ Kind Code ³ (if known)	Publication Date	realite of Faterites of Applicant	Pages, Columns, Lines, Where Relevant Passages or	т•				
Initials*	No.1				Relevant Figures Appear	1,				
					: .					
					:					
				_	:					
					:					
					:					
					:					
										

	والمراز			
Examiner Signature	Ain. Llock	Date Considered	5/10/05	:

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FROSTEGARD=1B

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Not Yet Assigned **Application Number** INFORMATION DISCLOSURE Even Date Herewith Filing Date Johan FROSTEGARD STATEMENT BY APPLICANT First Named Inventor Group Art Unit 1641 (use as many sheets as necessary) Examiner Name L. COOK

Attorney Docket Number

of 2

Sheet

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Cite Initials* No.1							
LX	2	AB	BALDO et al, "A specific, sensitive, and high capacity immunoassay for PAF". 1991). 26(12):1136-1139.				
			BARQUINERO, Jordi, et al "Antibodies Against Platelet-Activating Factor In Patients With Antiphospholipid Antibodies". Lupus, Vol. 3 (1994), pp. 55-58.				
			FROSTEGARD et al, "Association of Serum Antibodies to Heat-Shock Protein 65 With Borderline Hypertension", HYPERTENSION, 29(1), pp. 40-44, 1997.				
		ĄΕ	FROSTEGARD et al, "Platelet-Activating Factor and Oxidized LDL Induce Immune Activation by a Common Mechanism", ARTERIOSCLEROSIS, 17(5), pp 963-968, 1997.				
			HARRIS et al, "Evaluation of the Anti-Cardiolipin Antibody Test: Report of an International Workshop held 4 April 1986:, Clin. Exp Immunol, 1987 Apr; 68(1):215-222.				
			HIRASHIMA Y et al, "Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers". & ACTA Neurochir. (1995) 137(1-2):15- 18. (Dialog Information Services, File 154, MEDLINE, Dialog accession no. 08672149, Medline accession no. 96350619)				
		AH	KARASAWA et al, "Radioimmunoassay for platelet activating factor". Lipids. (1991). 26(12):1126-1129.				
			LEMNE et al, "Carotid Intima-Media Thickness and Plaque Borderline Hypertension" STROKE, 26(1); pp. 34-39; 1995				
UC	-		OSTERMANN et al, "The degradation of platelet activating factor in serum and its discriminative value in atherosclerotic patients." Thrombosis Research. (1998). 52:529-540.				

Examiner Signature Date Con	considered 5/10/	5
-----------------------------	------------------	---

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.